On September 27, 2021 Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, reported it has been named by Fierce Biotech as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry (Press release, Ribon Therapeutics, SEP 27, 2021, View Source [SID1234590293]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Ribon is pioneering the discovery and development of first-in-class precision therapies targeting stress support pathways in cancer and inflammation for patients with limited options," said Victoria Richon, Ph.D., President and Chief Executive Officer, Ribon Therapeutics. "We are thrilled to be recognized by Fierce Biotech among the industry’s leading innovators, reflecting the potential of our novel pipeline and approach. We look forward to building upon the momentum of our clinical programs."
"In 2020, we got to celebrate the best and brightest biotechs trying to dig the world out of the pandemic," said Annalee Armstrong, Senior Editor of Fierce Biotech. "Speaking with this year’s class of Fierce 15 winners showed us that not even a global pandemic can stop incredible innovations in medicine. We’re proud to showcase this esteemed group of emerging biotechs to the world."
Ribon’s lead program is RBN-2397, a PARP7 inhibitor in clinical development for the treatment of cancer. The expansion portion of the RBN-2397 Phase 1 trial is currently enrolling patients in a number of defined cohorts, including squamous cell carcinoma of the lung (SCCL). The dose-escalation portion of the Phase 1 trial, which evaluated RBN-2397 as a monotherapy in patients with advanced solid tumors, was completed earlier this year. In June 2021, data from this portion of the study was presented at the 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting and showed RBN-2397 was well tolerated with evidence of PARP7 inhibition and preliminary signs of antitumor activity. In the fourth quarter of 2021, Ribon plans to initiate a Phase 1b/2 study of RBN-2397 in combination with checkpoint inhibitors in patients with SCCL. Ribon is also advancing a second clinical candidate, RBN-3143, a potent and selective PARP14 inhibitor for the treatment of patients with inflammatory diseases.